National Institutes of Health: Thyroid Cancer, Papillary trials

The registry lists 19 Thyroid Cancer, Papillary studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 14 have results posted.

Phase 1 2Phase 2 15No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Studies on Tumors of the ThyroidRecruitingNCT00001160
• Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerActive, not recruitingNCT03914300Phase 2Results posted
• Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid CancerTerminatedNCT02408887Phase 2Results posted
• Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid CancerActive, not recruitingNCT02152995Phase 2Results posted
• Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid CancerCompletedNCT01811212Phase 2Results posted
• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid CancerCompletedNCT01502410Phase 2Results posted
• Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid CancerCompletedNCT01208051Phase 1/2Results posted
• Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine TherapyCompletedNCT00729157Phase 2Results posted
• Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive IodineCompletedNCT00559949Phase 2Results posted
• Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by SurgeryCompletedNCT00381641Phase 2Results posted
• Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid CancerCompletedNCT00134043Phase 2Results posted
• Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid CancerCompletedNCT00118248Phase 2Results posted
• Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine TherapyCompletedNCT00104871Phase 2Results posted
• Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive IodineCompletedNCT00098813Phase 2Results posted
• Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131CompletedNCT00085293Phase 2Results posted
• Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer TreatmentCompletedNCT01441154
• Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerTerminatedNCT00095693Phase 2
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1